The Japanese government plans to inject an additional 150 billion yen into Rapidus to support its advanced semiconductor manufacturing efforts. This funding targets the company's goal of mass-producing 2nm chips by 2027, a timeline that trails industry leader TSMC by approximately one year. The investment represents a significant escalation in state-backed support for Japan's domestic chip production capabilities.
Japanese government injects additional funding to support Rapidus advanced semiconductor manufacturing roadmap and 2nm mass production targets.
The Japanese government will inject 150 billion yen into Rapidus for 2nm mass production, with total subsidies reaching 2.9 trillion yen by 2027. The company aims to establish a 2nm process node that competes directly with current industry standards while simultaneously planning for future nodes like 1.4nm by 2029. This roadmap includes advanced packaging technologies such as 2.5D and 3D integration scheduled between 2028 and 2030.

The government investment covers roughly 60% of Rapidus's operational costs, though it limits state voting rights to 11.5 percent. The government investment covers 60% of costs but limits voting rights to 11.5%. The funding model prioritizes technological development over direct corporate control.
Total subsidies allocated to Rapidus through 2027 will reach 2.9 trillion yen, which equals approximately $18.1 billion USD according to current exchange rates. Rapidus aims to mass-produce the 2nm process by 2027, trailing TSMC by approximately one year. The company must meet these aggressive manufacturing targets to justify the continued flow of public funds.
Plans include developing a 1.4nm process by 2029 and implementing advanced packaging technologies between 2028 and 2030. The initiative represents a major national effort to secure technological sovereignty through advanced semiconductor manufacturing. This strategic roadmap outlines Japan's approach to achieving advanced chip fabrication capabilities through state-supported development.



Discussion
0 comments
Log in to join the thread with a thoughtful take, question, or correction.